9 research outputs found
ΠΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π²Π·Π°ΡΠΌΠΎΠ·Π²βΡΠ·ΠΊΡΠ² ΠΌΡΠΆ Π²ΠΌΡΡΡΠΎΠΌ ΠΎΡΠ½ΠΎΠ²Π½ΠΈΡ Π³ΡΡΠΏ ΠΠΠ Ρ Π½Π°ΡΡΠΎΠΉΡΡ ΡΠΎΠ±Π°ΡΠΎΡ ΠΊΡΠΎΠΏΠΈΠ²ΠΈ (Leonurus cardiaca) ΡΡΠ°Π²ΠΈ ΡΠ° ΡΡ ΠΏΡΠΈΡ ΠΎΡΡΠΎΠΏΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΡΡΡΡ
Topicality. Motherwort herb tincture is one of the most popular herbal remedies of sedative action. The disadvantage of this medicines is chemical composition volatility, and as a consequence, pharmacodynamics. Therefore, it is advisable to investigate BAS groups of Motherwort herb tincture having the greatest effect on its psychotropic activity and in the future to standardize the medicines precisely with their content.Aim. To determine the relationship between the main BAS groups content in Motherwort herb (Leonurus cardiaca) and its psychotropic activity in order to establish the parameters of this medicine standardization.Materials and methods. The object of the study was Motherwort herb tincture (series 15.04.16, produced at LTD βPharmaceutical factoryβ, Zhytomyr region., Stanishevka v.) and the main BAS groups complexes of isolated from. Determination of hydroxycinnamic derivatives acid, flavonoids and the sum of phenolic compounds, iridoids were carried out by spectrophotometric method and HPLC method. The psychotropic activity of the research objects were studied in the open field test in the NUPh Central Research Laboratory.Results and discussion. As a result of the chemical analysis of the tincture and obtained BAS complexes, 2 flavonoids (routine and catechin), 3 hydroxycinnamic acids (chlorogenic, coffeic and rosemarinic), 2 iridoids were identified and their quantitative contents were determined. It was established that Motherwort herb tincture and its components significantly decreases the sum of all types of psychotropic activity, mainly due to the reduction of motor activity. At the same time, it also shows a tendency to decrease the approximate research activity, indicating its sedative effect. The largest sedative activity in the smallest doses a complex of iridoids demonstrated. It should be taken into the account when this medicine is standardized.Conclusions. The study of qualitative composition and quantitative content of the main BAS groups (flavonoids, hydroxycinnamic acids, iridoids) in the Motherwort herb tincture and dry extracts based on it. The most sedative activity was shown by substances rich in iridoids, indicating the appropriateness of standardizingΒ Motherwort herb tincture on the content of this particular BAS group.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ. ΠΠ°ΡΡΠΎΠΉΠΊΠ° ΡΡΠ°Π²Ρ ΠΏΡΡΡΡΡΠ½ΠΈΠΊΠ° β ΠΎΠ΄ΠΈΠ½ ΠΈΠ· ΡΠ°ΠΌΡΡ
ΠΏΠΎΠΏΡΠ»ΡΡΠ½ΡΡ
ΡΠ°ΡΡΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΡΠ΅Π΄Π°ΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ. ΠΠ΅Π΄ΠΎΡΡΠ°ΡΠΊΠΎΠΌ ΡΡΠΎΠ³ΠΎ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΡΠ²Π»ΡΠ΅ΡΡΡ Π½Π΅ΠΏΠΎΡΡΠΎΡΠ½ΡΡΠ²ΠΎ Ρ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΎΡΡΠ°Π²Π° ΠΈ ΠΊΠ°ΠΊ ΡΠ»Π΅Π΄ΡΡΠ²ΠΈΠ΅, ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ. ΠΠΎΡΡΠΎΠΌΡ ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΡ, ΠΊΠ°ΠΊΠΈΠ΅ ΠΈΠΌΠ΅Π½Π½ΠΎ Π³ΡΡΠΏΠΏΡ ΠΠΠ Π½Π°ΡΡΠΎΠΉΠΊΠΈ ΠΏΡΡΡΡΡΠ½ΠΈΠΊΠ° ΠΎΠΊΠ°Π·ΡΠ²Π°ΡΡ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅Π΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° Π΅Π΅ ΠΏΡΠΈΡ
ΠΎΡΡΠΎΠΏΠ½ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ Π² Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅ΠΌ ΠΏΡΠΎΠ²ΠΎΠ΄ΡΡ ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·Π°ΡΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΈΠΌΠ΅Π½Π½ΠΎ ΠΏΠΎ ΠΈΡ
ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·ΠΈ ΠΌΠ΅ΠΆΠ΄Ρ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ΠΌ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ
Π³ΡΡΠΏΠΏ ΠΠΠ Π² Π½Π°ΡΡΠΎΠΉΠΊΠ΅ ΠΏΡΡΡΡΡΠ½ΠΈΠΊΠ° (Leonurus cardiaca) ΡΡΠ°Π²Ρ ΠΈ Π΅Π΅ ΠΏΡΠΈΡ
ΠΎΡΡΠΎΠΏΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ Π΄Π»Ρ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·Π°ΡΠΈΠΈ ΡΡΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ±ΡΠ΅ΠΊΡΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»Π° Π½Π°ΡΡΠΎΠΉΠΊΠ° ΠΏΡΡΡΡΡΠ½ΠΈΠΊΠ° ΠΏΡΠΎΠΌΡΡΠ»Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π° (ΡΠ΅ΡΠΈΡ 15.04.16, ΠΠΠ Β«Π€Π°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ°Π±ΡΠΈΠΊΠ°Β», ΠΠΈΡΠΎΠΌΠΈΡΡΠΊΠ°Ρ ΠΎΠ±Π»., Ρ. Π‘ΡΠ°Π½ΠΈΡΠ΅Π²ΠΊΠ°) ΠΈ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΡ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ
Π³ΡΡΠΏΠΏ ΠΠΠ, Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ
ΠΈΠ· Π½Π΅Π΅. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΡΡ
Π³ΠΈΠ΄ΡΠΎΠΊΡΠΈΠΊΠΎΡΠΈΡΠ½ΡΡ
ΠΊΠΈΡΠ»ΠΎΡ, ΡΠ»Π°Π²ΠΎΠ½ΠΎΠΈΠ΄ΠΎΠ², ΡΡΠΌΠΌΡ ΡΠ΅Π½ΠΎΠ»ΡΠ½ΡΡ
ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ, ΠΈΡΠΈΠ΄ΠΎΠΈΠ΄ΠΎΠ² ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΡΠΏΠ΅ΠΊΡΡΠΎΡΠΎΡΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΠΠΠ₯. ΠΡΠΈΡ
ΠΎΡΡΠΎΠΏΠ½ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΎΠ±ΡΠ΅ΠΊΡΠΎΠ² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΈΠ·ΡΡΠ°Π»ΠΈ Π² ΡΠ΅ΡΡΠ΅ ΠΎΡΠΊΡΡΡΠΎΠ³ΠΎ ΠΏΠΎΠ»Ρ Π² Π¦Π΅Π½ΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π½Π°ΡΡΠ½ΠΎ-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΡΠΊΠΎΠΉ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠΈΠΈ ΠΠ€Π°Π£.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΈΡ
ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. Π ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ Ρ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Π½Π°ΡΡΠΎΠΉΠΊΠΈ ΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ
ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΎΠ² ΠΠΠ Π±ΡΠ»ΠΎ ΠΈΠ΄Π΅Π½ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½ΠΎ 2 ΡΠ»Π°Π²ΠΎΠ½ΠΎΠΈΠ΄Π° (ΡΡΡΠΈΠ½ ΠΈ ΠΊΠ°ΡΠ΅Ρ
ΠΈΠ½), 3 Π³ΠΈΠ΄ΡΠΎΠΊΡΠΈΠΊΠΎΡΠΈΡΠ½ΡΠ΅ ΠΊΠΈΡΠ»ΠΎΡΡ (Ρ
Π»ΠΎΡΠΎΠ³Π΅Π½ΠΎΠ²ΡΡ, ΠΊΠΎΡΠ΅ΠΉΠ½ΡΡ ΠΈ ΡΠΎΠ·ΠΌΠ°ΡΠΈΠ½ΠΎΠ²ΡΡ), 2 ΠΈΡΠΈΠ΄ΠΎΠΈΠ΄Π° ΠΈ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ ΠΈΡ
ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π½Π°ΡΡΠΎΠΉΠΊΠ° ΠΏΡΡΡΡΡΠ½ΠΈΠΊΠ° ΠΈ Π΅Π΅ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΡ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎ ΡΠ½ΠΈΠΆΠ°ΡΡ ΡΡΠΌΠΌΡ Π²ΡΠ΅Ρ
Π²ΠΈΠ΄ΠΎΠ² ΠΏΡΠΈΡ
ΠΎΡΡΠΎΠΏΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ, Π² ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΌ Π·Π° ΡΡΠ΅Ρ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΡ Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ. ΠΡΠΈ ΡΡΠΎΠΌ ΠΎΠ½Π° ΡΠ°ΠΊΠΆΠ΅ ΠΎΠ±Π½Π°ΡΡΠΆΠΈΠ²Π°Π΅Ρ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΡ ΠΊ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΠΎΡΠΈΠ΅Π½ΡΠΈΡΠΎΠ²ΠΎΡΠ½ΠΎ-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ, ΡΡΠΎ ΡΠΊΠ°Π·ΡΠ²Π°Π΅Ρ Π½Π° Π΅Π΅ ΡΠ΅Π΄Π°ΡΠΈΠ²Π½ΠΎΠ΅ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅. ΠΠ°ΠΈΠ±ΠΎΠ»ΡΡΡΡ ΡΠ΅Π΄Π°ΡΠΈΠ²Π½ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π² Π½Π°ΠΈΠΌΠ΅Π½ΡΡΠ΅ΠΉ Π΄ΠΎΠ·Π΅ ΠΏΠΎΠΊΠ°Π·Π°Π» ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡ ΠΈΡΠΈΠ΄ΠΎΠΈΠ΄Π½ΡΡ
ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ, ΡΡΠΎ Π½ΡΠΆΠ½ΠΎ ΡΡΠΈΡΡΠ²Π°ΡΡ ΠΏΡΠΈ ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·Π°ΡΠΈΠΈ ΡΡΠΎΠ³ΠΎ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΡΡΠ΅Π΄ΡΡΠ²Π°.ΠΡΠ²ΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠΎΡΡΠ°Π²Π° ΠΈ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ
Π³ΡΡΠΏΠΏ ΠΠΠ (ΡΠ»Π°Π²ΠΎΠ½ΠΎΠΈΠ΄ΠΎΠ², Π³ΠΈΠ΄ΡΠΎΠΊΡΠΈΠΊΠΎΡΠΈΡΠ½ΡΡ
ΠΊΠΈΡΠ»ΠΎΡ, ΠΈΡΠΈΠ΄ΠΎΠΈΠ΄ΠΎΠ²) Π² Π½Π°ΡΡΠΎΠΉΠΊΠ΅ ΠΏΡΡΡΡΡΠ½ΠΈΠΊΠ° ΠΈ ΡΡΡ
ΠΈΡ
ΡΠΊΡΡΡΠ°ΠΊΡΠ°Ρ
Π½Π° Π΅Π΅ ΠΎΡΠ½ΠΎΠ²Π΅. ΠΠ°ΠΈΠ±ΠΎΠ»ΡΡΡΡ ΡΠ΅Π΄Π°ΡΠΈΠ²Π½ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΠΈ, Π±ΠΎΠ³Π°ΡΡΠ΅ ΠΈΡΠΈΠ΄ΠΎΠΈΠ΄Π°ΠΌΠΈ, ΡΡΠΎ ΡΠΊΠ°Π·ΡΠ²Π°Π΅Ρ Π½Π° ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎΡΡΡ ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·Π°ΡΠΈΠΈ Π½Π°ΡΡΠΎΠΉΠΊΠΈ ΠΏΡΡΡΡΡΠ½ΠΈΠΊΠ° ΠΏΠΎ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΠΈΠΌΠ΅Π½Π½ΠΎ ΡΡΠΎΠΉ Π³ΡΡΠΏΠΏΡ ΠΠΠ.ΠΠΊΡΡΠ°Π»ΡΠ½ΡΡΡΡ. ΠΠ°ΡΡΠΎΠΉΠΊΠ° ΡΡΠ°Π²ΠΈ ΡΠΎΠ±Π°ΡΠΎΡ ΠΊΡΠΎΠΏΠΈΠ²ΠΈ β ΠΎΠ΄ΠΈΠ½ Π· Π½Π°ΠΉΠ±ΡΠ»ΡΡ ΠΏΠΎΠΏΡΠ»ΡΡΠ½ΠΈΡ
ΡΠΎΡΠ»ΠΈΠ½Π½ΠΈΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡΠ² ΡΠ΅Π΄Π°ΡΠΈΠ²Π½ΠΎΡ Π΄ΡΡ. ΠΠ΅Π΄ΠΎΠ»ΡΠΊΠΎΠΌ ΡΡΠΎΠ³ΠΎ Π»ΡΠΊΠ°ΡΡΡΠΊΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ Ρ Π½Π΅ΠΏΠΎΡΡΡΠΉΠ½ΡΡΡΡ Ρ
ΡΠΌΡΡΠ½ΠΎΠ³ΠΎ ΡΠΊΠ»Π°Π΄Ρ Ρ ΡΠΊ Π½Π°ΡΠ»ΡΠ΄ΠΎΠΊ, ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ΄ΠΈΠ½Π°ΠΌΡΠΊΠΈ. Π’ΠΎΠΌΡ Π΄ΠΎΡΡΠ»ΡΠ½ΠΎ Π΄ΠΎΡΠ»ΡΠ΄ΠΈΡΠΈ, ΡΠΊΡ ΡΠ°ΠΌΠ΅ Π³ΡΡΠΏΠΈ ΠΠΠ Π½Π°ΡΡΠΎΠΉΠΊΠΈ ΡΠΎΠ±Π°ΡΠΎΡ ΠΊΡΠΎΠΏΠΈΠ²ΠΈ ΡΠΈΠ½ΡΡΡ Π½Π°ΠΉΠ±ΡΠ»ΡΡΠΈΠΉ Π²ΠΏΠ»ΠΈΠ² Π½Π° ΡΡ ΠΏΡΠΈΡ
ΠΎΡΡΠΎΠΏΠ½Ρ Π°ΠΊΡΠΈΠ²Π½ΡΡΡΡ ΡΠ° Π² ΠΏΠΎΠ΄Π°Π»ΡΡΠΎΠΌΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΡΠΈ ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·Π°ΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ ΡΠ°ΠΌΠ΅ Π·Π° ΡΡ
Π²ΠΌΡΡΡΠΎΠΌ.ΠΠ΅ΡΠ° Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ. ΠΠΈΠ·Π½Π°ΡΠΈΡΠΈ Π²Π·Π°ΡΠΌΠΎΠ·Π²βΡΠ·ΠΊΠΈ ΠΌΡΠΆ Π²ΠΌΡΡΡΠΎΠΌ ΠΎΡΠ½ΠΎΠ²Π½ΠΈΡ
Π³ΡΡΠΏ ΠΠΠ Ρ Π½Π°ΡΡΠΎΠΉΡΡ ΡΠΎΠ±Π°ΡΠΎΡ ΠΊΡΠΎΠΏΠΈΠ²ΠΈ (Leonurus cardiaca) ΡΡΠ°Π²ΠΈ ΡΠ° ΡΡ ΠΏΡΠΈΡ
ΠΎΡΡΠΎΠΏΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΡΡΡΡ Π΄Π»Ρ Π²ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π½Ρ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΡΠ² ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·Π°ΡΡΡ ΡΡΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ.ΠΠ°ΡΠ΅ΡΡΠ°Π»ΠΈ ΡΠ° ΠΌΠ΅ΡΠΎΠ΄ΠΈ. ΠΠ±βΡΠΊΡΠ°ΠΌΠΈ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π±ΡΠ»ΠΈ Π½Π°ΡΡΠΎΠΉΠΊΠ° ΡΠΎΠ±Π°ΡΠΎΡ ΠΊΡΠΎΠΏΠΈΠ²ΠΈ ΠΏΡΠΎΠΌΠΈΡΠ»ΠΎΠ²ΠΎΠ³ΠΎ Π²ΠΈΡΠΎΠ±Π½ΠΈΡΡΠ²Π° (ΡΠ΅ΡΡΡ 15.04.16, Π’ΠΠ Β«ΠΠΠ Β«Π€Π°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ½Π° ΡΠ°Π±ΡΠΈΠΊΠ°Β», ΠΠΈΡΠΎΠΌΠΈΡΡΡΠΊΠ° ΠΎΠ±Π»., Ρ. Π‘ΡΠ°Π½ΠΈΡΡΠ²ΠΊΠ°) ΡΠ° ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΈ ΠΎΡΠ½ΠΎΠ²Π½ΠΈΡ
Π³ΡΡΠΏ ΠΠΠ , Π²ΠΈΠ΄ΡΠ»Π΅Π½ΠΈΡ
Π· Π½Π΅Ρ. ΠΠΈΠ·Π½Π°ΡΠ΅Π½Π½Ρ ΠΏΠΎΡ
ΡΠ΄Π½ΠΈΡ
Π³ΡΠ΄ΡΠΎΠΊΡΠΈΠΊΠΎΡΠΈΡΠ½ΠΎΡ ΠΊΠΈΡΠ»ΠΎΡΠΈ, ΡΠ»Π°Π²ΠΎΠ½ΠΎΡΠ΄ΡΠ² ΡΠ° ΡΡΠΌΠΈ ΡΠ΅Π½ΠΎΠ»ΡΠ½ΠΈΡ
ΡΠΏΠΎΠ»ΡΠΊ, ΡΡΠΈΠ΄ΠΎΡΠ΄ΡΠ² ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΡΠΏΠ΅ΠΊΡΡΠΎΡΠΎΡΠΎΠΌΠ΅ΡΡΠΈΡΠ½ΠΈΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΡΠ° ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΠΠ Π₯. ΠΡΠΈΡ
ΠΎΡΡΠΎΠΏΠ½Ρ Π°ΠΊΡΠΈΠ²Π½ΡΡΡΡ ΠΎΠ±βΡΠΊΡΡΠ² Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π²ΠΈΠ²ΡΠ°Π»ΠΈ Ρ ΡΠ΅ΡΡΡ Π²ΡΠ΄ΠΊΡΠΈΡΠΎΠ³ΠΎ ΠΏΠΎΠ»Ρ Ρ Π¦Π΅Π½ΡΡΠ°Π»ΡΠ½ΡΠΉ Π½Π°ΡΠΊΠΎΠ²ΠΎ-Π΄ΠΎΡΠ»ΡΠ΄Π½ΡΠΉ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΡΡ ΠΠ€Π°Π£.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΠΈ ΡΠ° ΡΡ
ΠΎΠ±Π³ΠΎΠ²ΠΎΡΠ΅Π½Π½Ρ. Π ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Ρ
ΡΠΌΡΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΡΠ·Ρ Π½Π°ΡΡΠΎΠΉΠΊΠΈ ΡΠ° ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ
ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΡΠ² ΠΠΠ Π±ΡΠ»ΠΎ ΡΠ΄Π΅Π½ΡΠΈΡΡΠΊΠΎΠ²Π°Π½ΠΎ 2 ΡΠ»Π°Π²ΠΎΠ½ΠΎΡΠ΄ΠΈ (ΡΡΡΠΈΠ½ ΡΠ° ΠΊΠ°ΡΠ΅Ρ
ΡΠ½), 3 Π³ΡΠ΄ΡΠΎΠΊΡΠΈΠΊΠΎΡΠΈΡΠ½Ρ ΠΊΠΈΡΠ»ΠΎΡΠΈ (Ρ
Π»ΠΎΡΠΎΠ³Π΅Π½ΠΎΠ²Ρ, ΠΊΠ°Π²ΠΎΠ²Ρ ΡΠ° ΡΠΎΠ·ΠΌΠ°ΡΠΈΠ½ΠΎΠ²Ρ), 2 ΡΡΠΈΠ΄ΠΎΡΠ΄Π½Ρ ΡΠΏΠΎΠ»ΡΠΊΠΈ ΡΠ° Π²ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ ΡΡ
ΠΊΡΠ»ΡΠΊΡΡΠ½ΠΈΠΉ Π²ΠΌΡΡΡ. ΠΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΠΎ Π½Π°ΡΡΠΎΠΉΠΊΠ° ΡΠΎΠ±Π°ΡΠΎΡ ΠΊΡΠΎΠΏΠΈΠ²ΠΈ ΡΠ° ΡΡ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΈ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ½ΠΎ Π·Π½Π°ΡΡΡΠΎ Π·Π½ΠΈΠΆΡΡΡΡ ΡΡΠΌΡ Π²ΡΡΡ
Π²ΠΈΠ΄ΡΠ² ΠΏΡΠΈΡ
ΠΎΡΡΠΎΠΏΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ, Π² ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΌΡ Π·Π° ΡΠ°Ρ
ΡΠ½ΠΎΠΊ Π·ΠΌΠ΅Π½ΡΠ΅Π½Π½Ρ ΡΡΡ
ΠΎΠ²ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ. ΠΡΠΈ ΡΡΠΎΠΌΡ Π²ΠΎΠ½Π° ΡΠ°ΠΊΠΎΠΆ Π²ΠΈΡΠ²Π»ΡΡ ΡΠ΅Π½Π΄Π΅Π½ΡΡΡ Π΄ΠΎ Π·Π½ΠΈΠΆΠ΅Π½Π½Ρ ΠΎΡΡΡΠ½ΡΠΎΠ²Π½ΠΎ-Π΄ΠΎΡΠ»ΡΠ΄Π½ΠΈΡΡΠΊΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ, ΡΠΎ Π²ΠΊΠ°Π·ΡΡ Π½Π° ΡΡ ΡΠ΅Π΄Π°ΡΠΈΠ²Π½ΠΈΠΉ Π²ΠΏΠ»ΠΈΠ². ΠΠ°ΠΉΠ±ΡΠ»ΡΡΡ ΡΠ΅Π΄Π°ΡΠΈΠ²Π½Ρ Π°ΠΊΡΠΈΠ²Π½ΡΡΡΡ Ρ Π½Π°ΠΉΠΌΠ΅Π½ΡΡΠΉ Π΄ΠΎΠ·Ρ ΠΏΠΎΠΊΠ°Π·Π°Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡ ΡΡΠΈΠ΄ΠΎΡΠ΄Π½ΠΈΡ
ΡΠΏΠΎΠ»ΡΠΊ, ΡΠΎ ΠΏΠΎΡΡΡΠ±Π½ΠΎ Π²ΡΠ°Ρ
ΠΎΠ²ΡΠ²Π°ΡΠΈ ΠΏΡΠΈ ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·Π°ΡΡΡ ΡΡΠΎΠ³ΠΎ Π»ΡΠΊΠ°ΡΡΡΠΊΠΎΠ³ΠΎ Π·Π°ΡΠΎΠ±Ρ.ΠΠΈΡΠ½ΠΎΠ²ΠΊΠΈ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ ΡΠΊΡΡΠ½ΠΎΠ³ΠΎ ΡΠΊΠ»Π°Π΄Ρ ΡΠ° ΠΊΡΠ»ΡΠΊΡΡΠ½ΠΎΠ³ΠΎ Π²ΠΌΡΡΡΡ ΠΎΡΠ½ΠΎΠ²Π½ΠΈΡ
Π³ΡΡΠΏ ΠΠΠ (ΡΠ»Π°Π²ΠΎΠ½ΠΎΡΠ΄ΡΠ², Π³ΡΠ΄ΡΠΎΠΊΡΠΈΠΊΠΎΡΠΈΡΠ½ΠΈΡ
ΠΊΠΈΡΠ»ΠΎΡ, ΡΡΠΈΠ΄ΠΎΡΠ΄ΡΠ²) Ρ Π½Π°ΡΡΠΎΠΉΡΡ ΡΠΎΠ±Π°ΡΠΎΡ ΠΊΡΠΎΠΏΠΈΠ²ΠΈ ΡΠ° ΡΡΡ
ΠΈΡ
Π΅ΠΊΡΡΡΠ°ΠΊΡΠ°Ρ
Π½Π° ΡΡ ΠΎΡΠ½ΠΎΠ²Ρ. ΠΠ°ΠΉΠ±ΡΠ»ΡΡΡ ΡΠ΅Π΄Π°ΡΠΈΠ²Π½Ρ Π°ΠΊΡΠΈΠ²Π½ΡΡΡΡ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ ΡΡΠ±ΡΡΠ°Π½ΡΡΡ, Π±Π°Π³Π°ΡΡ Π½Π° ΡΡΠΈΠ΄ΠΎΡΠ΄ΠΈ, ΡΠΎ Π²ΠΊΠ°Π·ΡΡ Π½Π° Π΄ΠΎΡΡΠ»ΡΠ½ΡΡΡΡ ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·Π°ΡΡΡ Π½Π°ΡΡΠΎΠΉΠΊΠΈ ΡΠΎΠ±Π°ΡΠΎΡ ΠΊΡΠΎΠΏΠΈΠ²ΠΈ Π·Π° Π²ΠΌΡΡΡΠΎΠΌ ΡΠ°ΠΌΠ΅ ΡΡΡΡ Π³ΡΡΠΏΠΈ ΠΠΠ
Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis
BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-Analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-Analysis. RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: Total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]). CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodiumβglucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with reninβangiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years
ΠΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π°Π½ΡΠΈΠ³ΡΠΏΠΎΠΊΡΠΈΡΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π½ΠΎΠ²ΠΈΡ ΠΏΠΎΡ ΡΠ΄Π½ΠΈΡ Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΡ ΠΊΠΈΡΠ»ΠΎΡΠΈ
On the model of acute normobaric hypoxic hypoxia with hypercapnia the antihypoxic action of new derivatives of benzilic acid, namely β N-heterylamides of benzilic acid and products of their intramolecular cyclodehydration β thienolactams with five-, six- and seven membered cycles, respectively. Amides have also been studied on the basis of five-membered lactam β derivatives of thieno[3,4-b]pyrrol-6-carboxylic acid. According to the result of our studies the following regularities have been found. The cyclization products of benzilic acid amides significantly exceed the antihypoxic activity of the parent compounds, and it indicates the prospects of conducting the studies among the products of heterocyclization of N- heterylamides of benzilic acid. It should also be noted that modification of the ester group in position 6 of 2-oxo-3,3-diphenyl-2,3-dihydro-1Π-thieno[3,4-b]pyrrole-6-carboxylic acid appeared to be appropriate. Amides based on this compound (KMS-68, KMS-69, KMS-71) during the experiment showed the maximum life span of the animals under research.ΠΠ° ΠΌΠΎΠ΄Π΅Π»ΠΈ ΠΎΡΡΡΠΎΠΉ Π½ΠΎΡΠΌΠΎΠ±Π°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³ΠΈΠΏΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³ΠΈΠΏΠΎΠΊΡΠΈΠΈ Ρ Π³ΠΈΠΏΠ΅ΡΠΊΠ°ΠΏΠ½ΠΈΠ΅ΠΉ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π° Π°Π½ΡΠΈΠ³ΠΈΠΏΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π½ΠΎΠ²ΡΡ
ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΡΡ
Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ, Π° ΠΈΠΌΠ΅Π½Π½ΠΎ β N βΠ³Π΅ΡΠ΅ΡΠΈΠ»Π°ΠΌΠΈΠ΄ΠΎΠ² Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ ΠΈ ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² ΠΈΡ
Π²Π½ΡΡΡΠΈΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠΉ ΡΠΈΠΊΠ»ΠΎΠ΄Π΅Π³ΠΈΠ΄ΡΠ°ΡΠ°ΡΠΈΠΈ β ΡΠΈΠ΅Π½ΠΎΠ»Π°ΠΊΡΠ°ΠΌΠΎΠ² Ρ ΠΏΡΡΠΈ-, ΡΠ΅ΡΡΠΈ ΠΈ ΡΠ΅ΠΌΠΈΡΠ»Π΅Π½Π½ΡΠΌΠΈ ΡΠΈΠΊΠ»Π°ΠΌΠΈ. Π’Π°ΠΊΠΆΠ΅ Π±ΡΠ»ΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ Π°ΠΌΠΈΠ΄Ρ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΏΡΡΠΈΡΠ»Π΅Π½Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡΠ°ΠΌΠ° β ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΡΠ΅ ΡΠΈΠ΅Π½ΠΎ[3,4-b]ΠΏΠΈΡΡΠΎΠ»-6-ΠΊΠ°ΡΠ±ΠΎΠ½ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ. Π ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π±ΡΠ»ΠΈ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ ΡΠ»Π΅Π΄ΡΡΡΠΈΠ΅ Π·Π°ΠΊΠΎΠ½ΠΎΠΌΠ΅ΡΠ½ΠΎΡΡΠΈ: ΠΏΡΠΎΠ΄ΡΠΊΡΡ ΡΠΈΠΊΠ»ΠΈΠ·Π°ΡΠΈΠΈ Π°ΠΌΠΈΠ΄ΠΎΠ² Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΏΡΠ΅Π²ΠΎΡΡ
ΠΎΠ΄ΡΡ ΠΏΠΎ Π°Π½ΡΠΈΠ³ΠΈΠΏΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈΡΡ
ΠΎΠ΄Π½ΡΠ΅ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΡ, ΡΡΠΎ ΡΠΊΠ°Π·ΡΠ²Π°Π΅Ρ Π½Π° ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΈΠΌΠ΅Π½Π½ΠΎ ΡΡΠ΅Π΄ΠΈ ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² Π³Π΅ΡΠ΅ΡΠΎΡΠΈΠΊΠ»ΠΈΠ·Π°ΡΠΈΠΈ N-Π³Π΅ΡΠ΅ΡΠΈΠ»Π°ΠΌΠΈΠ΄ΠΎΠ² Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ. Π’Π°ΠΊΠΆΠ΅ ΡΠ»Π΅Π΄ΡΠ΅Ρ ΠΎΡΠΌΠ΅ΡΠΈΡΡ, ΡΡΠΎ ΡΠΌΠ΅ΡΡΠ½ΠΎΠΉ ΠΎΠΊΠ°Π·Π°Π»Π°ΡΡ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΡΡΠΈΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ Π² ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠΈ 6 2-ΠΎΠΊΡΠΎ-3,3-Π΄ΠΈΡΠ΅Π½ΠΈΠ»-2,3-Π΄ΠΈΠ³ΠΈΠ΄ΡΠΎ-1Π-ΡΠΈΠ΅Π½ΠΎ[3,4-b]ΠΏΠΈΡΡΠΎΠ»-6-ΠΊΠ°ΡΠ±ΠΎΠ½ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ. ΠΠΌΠΈΠ΄Ρ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΡΡΠΎΠ³ΠΎ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΡ (KMS-68, KMS-69, KMS-71) Π² Ρ
ΠΎΠ΄Π΅ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ° ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎ ΠΏΡΠΎΠ»ΠΎΠ½Π³ΠΈΡΠΎΠ²Π°Π»ΠΈ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΆΠΈΠ·Π½ΠΈ ΠΏΠΎΠ΄ΠΎΠΏΡΡΠ½ΡΡ
ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
.ΠΠ° ΠΌΠΎΠ΄Π΅Π»Ρ Π³ΠΎΡΡΡΠΎΡ Π½ΠΎΡΠΌΠΎΠ±Π°ΡΠΈΡΠ½ΠΎΡ Π³ΡΠΏΠΎΠΊΡΠΈΡΠ½ΠΎΡ Π³ΡΠΏΠΎΠΊΡΡΡ Π· Π³ΡΠΏΠ΅ΡΠΊΠ°ΠΏΠ½ΡΡΡ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π° Π°Π½ΡΠΈΠ³ΡΠΏΠΎΠΊΡΠΈΡΠ½Π° Π΄ΡΡ Π½ΠΎΠ²ΠΈΡ
ΠΏΠΎΡ
ΡΠ΄Π½ΠΈΡ
Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΡ ΠΊΠΈΡΠ»ΠΎΡΠΈ, Π° ΡΠ°ΠΌΠ΅ β N-Π³Π΅ΡΠ΅ΡΠΈΠ»Π°ΠΌΡΠ΄ΡΠ² Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΡ ΠΊΠΈΡΠ»ΠΎΡΠΈ ΡΠ° ΠΏΡΠΎΠ΄ΡΠΊΡΡΠ² ΡΡ
Π²Π½ΡΡΡΡΡΠ½ΡΠΎΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΡ ΡΠΈΠΊΠ»ΠΎΠ΄Π΅Π³ΡΠ΄ΡΠ°ΡΠ°ΡΡΡ β ΡΡΡΠ½ΠΎΠ»Π°ΠΊΡΠ°ΠΌΡΠ² Π· ΠΏβΡΡΠΈ-, ΡΠ΅ΡΡΠΈ- ΡΠ° ΡΠ΅ΠΌΠΈΡΠ»Π΅Π½Π½ΠΈΠΌΠΈ ΡΠΈΠΊΠ»Π°ΠΌΠΈ. Π’Π°ΠΊΠΎΠΆ Π±ΡΠ»ΠΈ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Ρ Π°ΠΌΡΠ΄ΠΈ Π½Π° ΠΎΡΠ½ΠΎΠ²Ρ ΠΏβΡΡΠΈΡΠ»Π΅Π½Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡΠ°ΠΌΡ β ΠΏΠΎΡ
ΡΠ΄Π½Ρ ΡΡΡΠ½ΠΎ[3,4-b]ΠΏΡΡΠΎΠ»-6-ΠΊΠ°ΡΠ±ΠΎΠ½ΠΎΠ²ΠΎΡ ΠΊΠΈΡΠ»ΠΎΡΠΈ. ΠΠ° ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌΠΈ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Ρ Π±ΡΠ»ΠΎ Π²ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ Π½Π°ΡΡΡΠΏΠ½Ρ Π·Π°ΠΊΠΎΠ½ΠΎΠΌΡΡΠ½ΠΎΡΡΡ: ΠΏΡΠΎΠ΄ΡΠΊΡΠΈ ΡΠΈΠΊΠ»ΡΠ·Π°ΡΡΡ Π°ΠΌΡΠ΄ΡΠ² Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΡ ΠΊΠΈΡΠ»ΠΎΡΠΈ Π·Π½Π°ΡΠ½ΠΎ ΠΏΠ΅ΡΠ΅Π²ΠΈΡΡΡΡΡ Π·Π° Π°Π½ΡΠΈΠ³ΡΠΏΠΎΠΊΡΠΈΡΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΡΡΡΡ Π²ΠΈΡ
ΡΠ΄Π½Ρ ΡΠΏΠΎΠ»ΡΠΊΠΈ, ΡΠΎ Π²ΠΊΠ°Π·ΡΡ Π½Π° ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡΡΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½Ρ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Ρ ΡΠ°ΠΌΠ΅ ΡΠ΅ΡΠ΅Π΄ ΠΏΡΠΎΠ΄ΡΠΊΡΡΠ² Π³Π΅ΡΠ΅ΡΠΎΡΠΈΠΊΠ»ΡΠ·Π°ΡΡΡ N-Π³Π΅ΡΠ΅ΡΠΈΠ»Π°ΠΌΡΠ΄ΡΠ² Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΡ ΠΊΠΈΡΠ»ΠΎΡΠΈ. Π‘Π»ΡΠ΄ ΡΠ°ΠΊΠΎΠΆ Π·Π°Π·Π½Π°ΡΠΈΡΠΈ, ΡΠΎ Π΄ΠΎΡΡΠ»ΡΠ½ΠΎΡ Π²ΠΈΡΠ²ΠΈΠ»Π°ΡΡ ΠΌΠΎΠ΄ΠΈΡΡΠΊΠ°ΡΡΡ Π΅ΡΡΠ΅ΡΠ½ΠΎΡ Π³ΡΡΠΏΠΈ Π² ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½Ρ 6 2-ΠΎΠΊΡΠΎ-3,3-Π΄ΠΈΡΠ΅Π½ΡΠ»-2,3-Π΄ΠΈΠ³ΡΠ΄ΡΠΎ-1Π-ΡΠΈΡΠ½ΠΎ[3,4-b]ΠΏΡΡΠΎΠ»-6-ΠΊΠ°ΡΠ±ΠΎΠ½ΠΎΠ²ΠΎΡ ΠΊΠΈΡΠ»ΠΎΡΠΈ. ΠΠΌΡΠ΄ΠΈ Π½Π° ΠΎΡΠ½ΠΎΠ²Ρ ΡΡΡΡ ΡΠΏΠΎΠ»ΡΠΊΠΈ (KMS-68, KMS-69, KMS-71) Π² Ρ
ΠΎΠ΄Ρ Π΅ΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΡ ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎ ΠΏΡΠΎΠ»ΠΎΠ½Π³ΠΎΠ²ΡΠ²Π°Π»ΠΈ ΡΡΠΈΠ²Π°Π»ΡΡΡΡ ΠΆΠΈΡΡΡ ΠΏΡΠ΄Π΄ΠΎΡΠ»ΡΠ΄Π½ΠΈΡ
ΡΠ²Π°ΡΠΈΠ½
ΠΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π°Π½ΡΠΈΠ³ΡΠΏΠΎΠΊΡΠΈΡΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π½ΠΎΠ²ΠΈΡ ΠΏΠΎΡ ΡΠ΄Π½ΠΈΡ Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΡ ΠΊΠΈΡΠ»ΠΎΡΠΈ
On the model of acute normobaric hypoxic hypoxia with hypercapnia the antihypoxic action of new derivatives of benzilic acid, namely β N-heterylamides of benzilic acid and products of their intramolecular cyclodehydration β thienolactams with five-, six- and seven membered cycles, respectively. Amides have also been studied on the basis of five-membered lactam β derivatives of thieno[3,4-b]pyrrol-6-carboxylic acid. According to the result of our studies the following regularities have been found. The cyclization products of benzilic acid amides significantly exceed the antihypoxic activity of the parent compounds, and it indicates the prospects of conducting the studies among the products of heterocyclization of N- heterylamides of benzilic acid. It should also be noted that modification of the ester group in position 6 of 2-oxo-3,3-diphenyl-2,3-dihydro-1Π-thieno[3,4-b]pyrrole-6-carboxylic acid appeared to be appropriate. Amides based on this compound (KMS-68, KMS-69, KMS-71) during the experiment showed the maximum life span of the animals under research.ΠΠ° ΠΌΠΎΠ΄Π΅Π»ΠΈ ΠΎΡΡΡΠΎΠΉ Π½ΠΎΡΠΌΠΎΠ±Π°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³ΠΈΠΏΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³ΠΈΠΏΠΎΠΊΡΠΈΠΈ Ρ Π³ΠΈΠΏΠ΅ΡΠΊΠ°ΠΏΠ½ΠΈΠ΅ΠΉ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π° Π°Π½ΡΠΈΠ³ΠΈΠΏΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π½ΠΎΠ²ΡΡ
ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΡΡ
Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ, Π° ΠΈΠΌΠ΅Π½Π½ΠΎ β N βΠ³Π΅ΡΠ΅ΡΠΈΠ»Π°ΠΌΠΈΠ΄ΠΎΠ² Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ ΠΈ ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² ΠΈΡ
Π²Π½ΡΡΡΠΈΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠΉ ΡΠΈΠΊΠ»ΠΎΠ΄Π΅Π³ΠΈΠ΄ΡΠ°ΡΠ°ΡΠΈΠΈ β ΡΠΈΠ΅Π½ΠΎΠ»Π°ΠΊΡΠ°ΠΌΠΎΠ² Ρ ΠΏΡΡΠΈ-, ΡΠ΅ΡΡΠΈ ΠΈ ΡΠ΅ΠΌΠΈΡΠ»Π΅Π½Π½ΡΠΌΠΈ ΡΠΈΠΊΠ»Π°ΠΌΠΈ. Π’Π°ΠΊΠΆΠ΅ Π±ΡΠ»ΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ Π°ΠΌΠΈΠ΄Ρ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΏΡΡΠΈΡΠ»Π΅Π½Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡΠ°ΠΌΠ° β ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΡΠ΅ ΡΠΈΠ΅Π½ΠΎ[3,4-b]ΠΏΠΈΡΡΠΎΠ»-6-ΠΊΠ°ΡΠ±ΠΎΠ½ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ. Π ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π±ΡΠ»ΠΈ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ ΡΠ»Π΅Π΄ΡΡΡΠΈΠ΅ Π·Π°ΠΊΠΎΠ½ΠΎΠΌΠ΅ΡΠ½ΠΎΡΡΠΈ: ΠΏΡΠΎΠ΄ΡΠΊΡΡ ΡΠΈΠΊΠ»ΠΈΠ·Π°ΡΠΈΠΈ Π°ΠΌΠΈΠ΄ΠΎΠ² Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΏΡΠ΅Π²ΠΎΡΡ
ΠΎΠ΄ΡΡ ΠΏΠΎ Π°Π½ΡΠΈΠ³ΠΈΠΏΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈΡΡ
ΠΎΠ΄Π½ΡΠ΅ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΡ, ΡΡΠΎ ΡΠΊΠ°Π·ΡΠ²Π°Π΅Ρ Π½Π° ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΈΠΌΠ΅Π½Π½ΠΎ ΡΡΠ΅Π΄ΠΈ ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² Π³Π΅ΡΠ΅ΡΠΎΡΠΈΠΊΠ»ΠΈΠ·Π°ΡΠΈΠΈ N-Π³Π΅ΡΠ΅ΡΠΈΠ»Π°ΠΌΠΈΠ΄ΠΎΠ² Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ. Π’Π°ΠΊΠΆΠ΅ ΡΠ»Π΅Π΄ΡΠ΅Ρ ΠΎΡΠΌΠ΅ΡΠΈΡΡ, ΡΡΠΎ ΡΠΌΠ΅ΡΡΠ½ΠΎΠΉ ΠΎΠΊΠ°Π·Π°Π»Π°ΡΡ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΡΡΠΈΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ Π² ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠΈ 6 2-ΠΎΠΊΡΠΎ-3,3-Π΄ΠΈΡΠ΅Π½ΠΈΠ»-2,3-Π΄ΠΈΠ³ΠΈΠ΄ΡΠΎ-1Π-ΡΠΈΠ΅Π½ΠΎ[3,4-b]ΠΏΠΈΡΡΠΎΠ»-6-ΠΊΠ°ΡΠ±ΠΎΠ½ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ. ΠΠΌΠΈΠ΄Ρ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΡΡΠΎΠ³ΠΎ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΡ (KMS-68, KMS-69, KMS-71) Π² Ρ
ΠΎΠ΄Π΅ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ° ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎ ΠΏΡΠΎΠ»ΠΎΠ½Π³ΠΈΡΠΎΠ²Π°Π»ΠΈ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΆΠΈΠ·Π½ΠΈ ΠΏΠΎΠ΄ΠΎΠΏΡΡΠ½ΡΡ
ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
.ΠΠ° ΠΌΠΎΠ΄Π΅Π»Ρ Π³ΠΎΡΡΡΠΎΡ Π½ΠΎΡΠΌΠΎΠ±Π°ΡΠΈΡΠ½ΠΎΡ Π³ΡΠΏΠΎΠΊΡΠΈΡΠ½ΠΎΡ Π³ΡΠΏΠΎΠΊΡΡΡ Π· Π³ΡΠΏΠ΅ΡΠΊΠ°ΠΏΠ½ΡΡΡ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π° Π°Π½ΡΠΈΠ³ΡΠΏΠΎΠΊΡΠΈΡΠ½Π° Π΄ΡΡ Π½ΠΎΠ²ΠΈΡ
ΠΏΠΎΡ
ΡΠ΄Π½ΠΈΡ
Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΡ ΠΊΠΈΡΠ»ΠΎΡΠΈ, Π° ΡΠ°ΠΌΠ΅ β N-Π³Π΅ΡΠ΅ΡΠΈΠ»Π°ΠΌΡΠ΄ΡΠ² Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΡ ΠΊΠΈΡΠ»ΠΎΡΠΈ ΡΠ° ΠΏΡΠΎΠ΄ΡΠΊΡΡΠ² ΡΡ
Π²Π½ΡΡΡΡΡΠ½ΡΠΎΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΡ ΡΠΈΠΊΠ»ΠΎΠ΄Π΅Π³ΡΠ΄ΡΠ°ΡΠ°ΡΡΡ β ΡΡΡΠ½ΠΎΠ»Π°ΠΊΡΠ°ΠΌΡΠ² Π· ΠΏβΡΡΠΈ-, ΡΠ΅ΡΡΠΈ- ΡΠ° ΡΠ΅ΠΌΠΈΡΠ»Π΅Π½Π½ΠΈΠΌΠΈ ΡΠΈΠΊΠ»Π°ΠΌΠΈ. Π’Π°ΠΊΠΎΠΆ Π±ΡΠ»ΠΈ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Ρ Π°ΠΌΡΠ΄ΠΈ Π½Π° ΠΎΡΠ½ΠΎΠ²Ρ ΠΏβΡΡΠΈΡΠ»Π΅Π½Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡΠ°ΠΌΡ β ΠΏΠΎΡ
ΡΠ΄Π½Ρ ΡΡΡΠ½ΠΎ[3,4-b]ΠΏΡΡΠΎΠ»-6-ΠΊΠ°ΡΠ±ΠΎΠ½ΠΎΠ²ΠΎΡ ΠΊΠΈΡΠ»ΠΎΡΠΈ. ΠΠ° ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌΠΈ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Ρ Π±ΡΠ»ΠΎ Π²ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ Π½Π°ΡΡΡΠΏΠ½Ρ Π·Π°ΠΊΠΎΠ½ΠΎΠΌΡΡΠ½ΠΎΡΡΡ: ΠΏΡΠΎΠ΄ΡΠΊΡΠΈ ΡΠΈΠΊΠ»ΡΠ·Π°ΡΡΡ Π°ΠΌΡΠ΄ΡΠ² Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΡ ΠΊΠΈΡΠ»ΠΎΡΠΈ Π·Π½Π°ΡΠ½ΠΎ ΠΏΠ΅ΡΠ΅Π²ΠΈΡΡΡΡΡ Π·Π° Π°Π½ΡΠΈΠ³ΡΠΏΠΎΠΊΡΠΈΡΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΡΡΡΡ Π²ΠΈΡ
ΡΠ΄Π½Ρ ΡΠΏΠΎΠ»ΡΠΊΠΈ, ΡΠΎ Π²ΠΊΠ°Π·ΡΡ Π½Π° ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡΡΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½Ρ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Ρ ΡΠ°ΠΌΠ΅ ΡΠ΅ΡΠ΅Π΄ ΠΏΡΠΎΠ΄ΡΠΊΡΡΠ² Π³Π΅ΡΠ΅ΡΠΎΡΠΈΠΊΠ»ΡΠ·Π°ΡΡΡ N-Π³Π΅ΡΠ΅ΡΠΈΠ»Π°ΠΌΡΠ΄ΡΠ² Π±Π΅Π½Π·ΠΈΠ»ΠΎΠ²ΠΎΡ ΠΊΠΈΡΠ»ΠΎΡΠΈ. Π‘Π»ΡΠ΄ ΡΠ°ΠΊΠΎΠΆ Π·Π°Π·Π½Π°ΡΠΈΡΠΈ, ΡΠΎ Π΄ΠΎΡΡΠ»ΡΠ½ΠΎΡ Π²ΠΈΡΠ²ΠΈΠ»Π°ΡΡ ΠΌΠΎΠ΄ΠΈΡΡΠΊΠ°ΡΡΡ Π΅ΡΡΠ΅ΡΠ½ΠΎΡ Π³ΡΡΠΏΠΈ Π² ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½Ρ 6 2-ΠΎΠΊΡΠΎ-3,3-Π΄ΠΈΡΠ΅Π½ΡΠ»-2,3-Π΄ΠΈΠ³ΡΠ΄ΡΠΎ-1Π-ΡΠΈΡΠ½ΠΎ[3,4-b]ΠΏΡΡΠΎΠ»-6-ΠΊΠ°ΡΠ±ΠΎΠ½ΠΎΠ²ΠΎΡ ΠΊΠΈΡΠ»ΠΎΡΠΈ. ΠΠΌΡΠ΄ΠΈ Π½Π° ΠΎΡΠ½ΠΎΠ²Ρ ΡΡΡΡ ΡΠΏΠΎΠ»ΡΠΊΠΈ (KMS-68, KMS-69, KMS-71) Π² Ρ
ΠΎΠ΄Ρ Π΅ΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΡ ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎ ΠΏΡΠΎΠ»ΠΎΠ½Π³ΠΎΠ²ΡΠ²Π°Π»ΠΈ ΡΡΠΈΠ²Π°Π»ΡΡΡΡ ΠΆΠΈΡΡΡ ΠΏΡΠ΄Π΄ΠΎΡΠ»ΡΠ΄Π½ΠΈΡ
ΡΠ²Π°ΡΠΈΠ½
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
International audienc
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Background: People with diabetes and kidney disease have a high risk of cardiovascular events and progression of kidney disease. Sodium glucose co-transporter 2 inhibitors lower plasma glucose by reducing the uptake of filtered glucose in the kidney tubule, leading to increased urinary glucose excretion. They have been repeatedly shown to induce modest natriuresis and reduce HbA1c, blood pressure, weight, and albuminuria in patients with type 2 diabetes. However, the effects of these agents on kidney and cardiovascular events have not been extensively studied in patients with type 2 diabetes and established kidney disease. Methods: The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial aims to compare the efficacy and safety of canagliflozin ΓΒversus placebo at preventing clinically important kidney and cardiovascular outcomes in patients with diabetes and established kidney disease. CREDENCE is a randomized, double-blind, event-driven, placebo-controlled trial set in in 34 countries with a projected duration of Γ’\u88ΒΌ5.5 years and enrolling 4,401 adults with type 2 diabetes, estimated glomerular filtration rate Γ’\u89Β₯30 to 300 to Γ’\u89Β€5,000 mg/g). The study has 90% power to detect a 20% reduction in the risk of the primary outcome (ΓΒ± = 0.05), the composite of end-stage kidney disease, doubling of serum creatinine, and renal or cardiovascular death. Conclusion: CREDENCE will provide definitive evidence about the effects of canagliflozin on renal (and cardiovascular) outcomes in patients with type 2 diabetes and established kidney disease. Trial Registration: EudraCT number: 2013-004494-28; ClinicalTrials.gov identifier: NCT02065791